Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BillionToOneBLLN -0.25%15 Market Cap is $4,484.2 Mil as of Aug. 21, 2026. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, BillionToOne ranks better than 86.57% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BillionToOne's share price for the quarter that ended in Jun. 2026 was $119.98. BillionToOne's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 46.8 Mil. Therefore, BillionToOne's market cap for the quarter that ended in Jun. 2026 was $5,618.3 Mil.
BillionToOne's quarterly market cap
declined
from Dec. 2025 ($3,748.7 Mil) to Mar. 2026 ($3,629.7 Mil) but then
increased
from Mar. 2026 ($3,629.7 Mil) to Jun. 2026 ($5,618.3 Mil).
BillionToOne's annual market cap
stayed the same
from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil) but then
increased
from Dec. 2024 ($0.0 Mil) to Dec. 2025 ($3,748.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BillionToOne's Enterprise Value for Today is $4,079.5 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BillionToOne Market Cap Related Terms
BillionToOne Market Cap Historical Data
* Premium members only.
The historical data trend for BillionToOne's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BillionToOne's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Market Cap distribution charts can be found below:
* The bar in red indicates where BillionToOne's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BillionToOne's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne (BLLN) has a Market Cap of $4,484.2 Mil as of Aug. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #29 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 13.4%.
Is BillionToOne's Market Cap too high?
BillionToOne's current Market Cap is $4,484.2 Mil. The Medical Diagnostics & Research industry median Market Cap is 63.57. BillionToOne's value of $4,484.2 Mil is 6954.3% above this industry median. Based on the distribution chart, BillionToOne ranks #29 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Market Cap compare to TWST and SHC?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #29 out of 216 companies for Market Cap. This places BillionToOne in the top 13% of its industry — outperforming the majority of peers. The industry median Market Cap is 63.57. BillionToOne's value of $4,484.2 Mil is 6954.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 63.57, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current Market Cap of $4,484.2 Mil is 6954.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 63.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current Market Cap is $4,484.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Market Cap of $4,484.2 Mil. The current Market Cap is $4,484.2 Mil and 6954.3% above the Medical Diagnostics & Research industry median of 63.57. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BillionToOne (BLLN), the current Market Cap is $4,484.2 Mil as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score
Get the complete analysis for BLLN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 
